273 Participants Needed
UCB Biopharma SRL logo

UCB1381 for Eczema

Recruiting at 25 trial locations
UC
Overseen ByUCB Cares
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: UCB Biopharma SRL
Must be taking: Topical corticosteroids

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new drug called UCB1381 to see if it is safe and well-tolerated when given through a vein or under the skin. The study includes both healthy individuals and those with atopic dermatitis, a condition causing red, itchy skin. The drug likely works by calming the immune system to reduce skin inflammation.

Will I have to stop taking my current medications?

Yes, participants must stop taking certain medications before joining the trial. Specifically, those with atopic dermatitis must stop using topical therapies for 2 weeks and systemic therapies for 4 weeks before the study starts. Other medications, except for some exceptions like contraceptives and occasional pain relievers, must be stopped 14 days before the study.

Who Is on the Research Team?

UC

UCB Cares

Principal Investigator

001 844 599 2273 (UCB)

Are You a Good Fit for This Trial?

This trial is for healthy adults aged 18-55 with a BMI of 18-30 kg/m2, and adults aged 18-65 with moderate to severe atopic dermatitis (AD), a BMI of 18-35 kg/m2, and certain severity scores. Participants must not have used specific treatments recently or have conditions that could affect the study.

Inclusion Criteria

Your body mass index (BMI) is between 18 and 30.
I have had severe skin eczema for over a year, not better with usual creams.
I agree to use birth control during the study.
See 6 more

Exclusion Criteria

Part B Participants with moderate to severe Atopic dermatitis (AtD) must not have participated in another study of an IMP within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit or is currently participating in another study of an IMP
Part B Participants with moderate to severe Atopic dermatitis (AtD) must not have a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, electrocardiogram (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, metabolism, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data
I have moderate to severe Atopic dermatitis and haven't been in studies for IL-13 or IL-22 or JAK inhibitors recently.
See 12 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Single-Ascending Dose (Part A)

Participants receive a single dose of UCB1381 or placebo intravenously or subcutaneously to assess safety and tolerability

12 weeks
Multiple visits for dosing and monitoring

Repeat-Dose (Part B)

Participants with moderate to severe atopic dermatitis receive repeated doses of UCB1381 or placebo intravenously to assess safety, pharmacokinetics, and efficacy

22 weeks
Regular visits for dosing and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • UCB1381
Trial Overview The safety and effects of UCB1381 are being tested in two parts: Part A tests single doses on healthy participants; Part B tests repeated doses on those with AD compared to placebo. The focus is on how well it works for AD after multiple doses.
How Is the Trial Designed?
12Treatment groups
Experimental Treatment
Placebo Group
Group I: UCB1381 dosing regime 9 in Part BExperimental Treatment1 Intervention
Group II: UCB1381 dosing regime 8 in Part AExperimental Treatment1 Intervention
Group III: UCB1381 dosing regime 7 in Part AExperimental Treatment1 Intervention
Group IV: UCB1381 dosing regime 6 in Part AExperimental Treatment1 Intervention
Group V: UCB1381 dosing regime 5 in Part AExperimental Treatment1 Intervention
Group VI: UCB1381 dosing regime 4 in Part AExperimental Treatment1 Intervention
Group VII: UCB1381 dosing regime 3 in Part AExperimental Treatment1 Intervention
Group VIII: UCB1381 dosing regime 2 in Part AExperimental Treatment1 Intervention
Group IX: UCB1381 dosing regime 1 in Part AExperimental Treatment1 Intervention
Group X: Placebo iv Arm Part APlacebo Group1 Intervention
Group XI: Placebo sc Arm Part APlacebo Group1 Intervention
Group XII: Placebo iv Arm Part BPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

UCB Biopharma SRL

Lead Sponsor

Trials
118
Recruited
23,200+

Jean-Christophe Tellier

UCB Biopharma SRL

Chief Executive Officer since 2015

MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD

Dr. Iris Loew-Friedrich

UCB Biopharma SRL

Chief Medical Officer since 2014

MD from University of Leuven, PhD in Medical Sciences from University of Leuven

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security